Nature Medicine - Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial

Subscription and open access journals from Sage, the world's leading independent academic publisher.

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...

KEYNOTE-991 trial shows no survival benefit from adding pembrolizumab to enzalutamide and ADT in mHSPC.

The use of antidepressants — particularly selective serotonin re-uptake inhibitors (SSRIs) — are associated with a “statistically substantial increased risk” of postural hypotension (PH) in older…

The new custom analysis feature on OpenPrescribing Hospitals.

The cancer centre at the Brighton hospital will include more inpatient beds, the NHS trust says.

Prostate Cancer and Prostatic Diseases - Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II...

Many cancer patients suffer sexual health problems but this important quality of life indicator is woefully ignored

Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.

Objective To evaluate the area-based incidence of metastatic prostate cancer at diagnosis, reflecting the risk of late-stage diagnosis, and overall prostate cancer incidence, reflecting the risk of ov...

We’ve made OpenPrescribing Hospitals platform to all with our first feature. Read more to see how you can access it.

Estate agent who quit after being denied a ‘symbolically significant’ seat was right to view it as demotion, panel says